Podcasts about blood cancer

Right Thinking with Steve Coplon.This week's show is called "This Is Not Our Home." Please tune in and hear Steve share stories of his deep faith, which gives him the strength and courage to carry on with an attitude of thankfulness despite living with tremendous adversity. This show will help you face your hardships.In this episode, I reflect on perseverance through a deep faith that emphasizes our spiritual existence beyond the physical world. Titled "This Is Not Our Home," I share lessons learned from my friendship with Steve Thomas, whose blindness taught me to maintain a higher perspective amidst adversity.Drawing from martial arts, I highlight adaptability and the warrior mindset. Anchored in scripture, I encourage listeners to cultivate gratitude and trust in the Lord's plan, transforming challenges into opportunities for growth and resilience.https://www.talknetworkradio.com/hosts/right-thinking

Alexandra Wilson passed away just 10 months after being diagnosed with Acute Lymphoblastic Leukemia in March of 2002, from this Blood Cancer that normally has a very high cure rate. Her twin sister Arianna will talk about her sister and about her role as the now official Executive Director of the Alex's Team Foundation which was named in Alexandra's honor, and helps in many ways the cause of Pediatric Cancer, with an emphasis on the Pediatric Cancer Nursing Community. 

Rory McGowan is joined by Dr Juho Jalkanen from Faron Pharmaceuticals. In this episode they discuss a new blood cancer trial has shown highly promising results, particularly for patients who have relapsed or live with hard-to-treat forms of the disease. https://faron.com/ 

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "Afterword – the Reunion" with guest Johnnie Lloyd. Tune in to this follow-on to Right Thinking: Life Money Relationships, and hear Steve and Johnnie reunite to discuss the immortal words of Bob Dylan's "the Times They are A-Changin'." You will be inspired to modify the way that you handle your finances as we are living in increasingly uncertain economic times. This show is guaranteed to add value to your life.https://www.talknetworkradio.com/hosts/right-thinking

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "Victory: Enjoying the Fruits of Your Labor," with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie complete their series Right Thinking: Life, Money, Relationships. Now that you have decided to take control of your life and put in the work, go forth and succeed.https://www.talknetworkradio.com/hosts/right-thinking

It's a big day at WCCO, a whole day (6a-6p) dedicated to raising money for NMDP as they fight blood cancers and disorders and aim to create a world where every patient can receive their life-saving cell therapy. Jason and Dan are live at NMDP and are joined by Brent Frederick from Jester Concepts and Ethan Walsh and his family . NMDP is a global nonprofit leader in cell therapy, helping save the lives of patients with blood cancers and disorders.

It's a big day at WCCO, a whole day (6a-6p) dedicated to raising money for NMDP as they fight blood cancers and disorders and aim to create a world where every patient can receive their life-saving cell therapy. Florian Riedel manages the Four Seasons and he joins Jason to talk about the Four Seasons Package they're donating which includes 2-nights in an executive suite, daily breakfast at Mara for two and complimentary valet parking for one vehicle. Florian details some of the things he looks forward to every day working at the Four Seasons and what “executive suite experience” means at their hotel. During the second half of the hour Jason we collect bids for the Twins "Dugout Buddies" Package. Experience provides 4 tickets to a mutually-agreed upon date/game...and includes the opportunity for 2 kids to meet Twins players on the field during batting practice and pregame activities. Kids are sat in padded chairs right in front of the Twins dugout and players come and greet them as they come through for BP.

It's a big day at WCCO, not just Chad's birthday but its the Cure Blood Cancer Radio Auction in partnership with NMDP! We kick the bidding items off with a dinner for two in the famous Sid Hartman booth at Murray's Steakhouse! Chad is joined by Erica Jensen (Senior Vice President, Innovation, Strategy & Marketing at NMDP. NMDP is a global nonprofit leader in cell therapy, helping save the lives of patients with blood cancers and disorders. NMDP aims to create a world where every patient can receive their life-saving cell therapy.

It's a big day at WCCO, not just Chad's birthday but its the Cure Blood Cancer Radio Auction in partnership with NMDP! Chad is joined by Todd Peterson who is the Executive Director with NMDP. Chad and Todd talk about what brought him to working with NMDP and the interactions they have with people when they reach out to the organization after being touched by blood cancer.. They take bids on the Twins Executive Balcony package where 20 ticket winners join Chad Hartman, Dave Harrigan for the Thursday, June 26th 12:10p game vs Seattle Mariners. The experience includes fully catered food & beverage from one of the coolest private viewing spots at Target Field! In the second half of the hour Chad and Dave take bids on the TPC/3M Package which includes golf/tee times for 4 at the exclusive TPC club in Blaine...PLUS, 4 tickets to the 3rd round at the 3M Open, on Saturday July 26th - which includes a concert that evening with country music recording & touring artist Lee Brice.

Chad is joined by Jordana Green to kick off the second hour at the Cure Blood Cancer Radio Auction alongside NMDP. We gather bids for the the MN United Gameday VIP Experience with Chad Hartman which includes personal “chalk talk” with Minnesota soccer legend Manny Lagos, a mini tour of Alliance Stadium before the game and the opportunity to watch warm ups from the home team bench! NMDP aims to create a world where every patient can receive their life-saving cell therapy.

We talk about the discovery and its implications for millions of people.

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "Legacy: Living a Transformational Life" with guest Johnnie Lloyd.  Tune in and hear Steve and Johnnie continue their series Right Thinking: Life, Money, Relationships. Your financial literacy skills can help lift you to higher heights where you can leave a mark that cannot be erased.https://www.talknetworkradio.com/hosts/right-thinking

Sara-Jayne Makwala King in for Pippa Hudson speaks to Andrew Parker who’s little boy Leo is battling a rare disorder that prevents his bone marrow from producing blood cells. Lunch with Pippa Hudson is CapeTalk’s mid-afternoon show. This 2-hour respite from hard news encourages the audience to take the time to explore, taste, read and reflect. The show - presented by former journalist, baker and water sports enthusiast Pippa Hudson - is unashamedly lifestyle driven. Popular features include a daily profile interview #OnTheCouch at 1:10pm. Consumer issues are in the spotlight every Wednesday while the team also unpacks all things related to health, wealth & the environment. Thank you for listening to a podcast from Lunch with Pippa Hudson Listen live on Primedia+ weekdays between 13:00 and 15:00 (SA Time) to Lunch with Pippa Hudson broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/MdSlWEs or find all the catch-up podcasts here https://buff.ly/fDJWe69 Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Thursday May 22, 2025 Common Energy Drink Ingredient Linked to Blood Cancer

The Leukaemia Foundation says one in 12 people in Australia are at risk of being diagnosed with a blood cancer, but a lack of awareness about symptoms means many cancers go undiagnosed for longer periods. The Foundation says blood cancers are likely to overtake other cancers by 2035. - ल्युकेमिया फाउन्डेसनका अनुसार अस्ट्रेलियामा हरेक १२ मध्ये एक व्यक्ति ब्लड वा रगतको क्यान्सरको जोखिममा छन्। तर लक्षणबारे पर्याप्त जानकारी नहुँदा धेरैजसोमा ढिलो मात्र रोग पत्ता लाग्ने गरेको छ। सन् २०३५ सम्ममा ब्लड क्यान्सरको सङ्क्रमण अन्य क्यान्सरभन्दा धेरै हुने सम्भावना बढेको फाउन्डेसनको भनाइ छ।

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is "Investing: Turning Your Goals into Reality," with guest Johnnie Lloyd. Please tune in to hear Steve and Johnnie continue their series Right Thinking: Life, Money, Relationships. Once you have made the choice to take control of your life through disciplined personal financial management, there are many ways you can put your money to work for you.https://www.talknetworkradio.com/hosts/right-thinking

Joao wants to know what happens when stem cells of our own, which have been cultivated outside the body, are reintroduced to the bloodstream. This got James Tytko thinking about autologous stem cell transplants, used as a treatment for some forms of blood cancer. He asked Tania Dexter, haematology registrar, and senior medical officer at the Anthony Nolan Institute, to help explain... Like this podcast? Please help us by supporting the Naked Scientists

The Leukaemia Foundation says one in 12 people in Australia are at risk of being diagnosed with a blood cancer, but a lack of awareness about symptoms means many cancers go undiagnosed for longer periods.The Foundation says blood cancers are likely to overtake other cancers by 2035. - لیوکیمیا فاؤنڈیشن کا کہنا ہے کہ آسٹریلیا میں ہر بارہ میں سے ایک فرد کو خون کے کینسر کی تشخیص کا خطرہ لاحق ہے، لیکن علامات سے متعلق آگاہی کی کمی کی وجہ سے اکثر کیسز دیر سے تشخیص ہوتے ہیں۔ فاؤنڈیشن کے مطابق خون کا کینسر 2035 تک دیگر اقسام کے کینسر سے بڑھ جائے گا۔

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "An Apple a Day Keeps the Doctor Away" with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series Right Thinking: Life, Money, Relationships. This week taking a look at how health issues can have a devasting impact on your life and how you want to put yourself in a position to simply do the best you can.https://www.talknetworkradio.com/hosts/right-thinking

The Leukaemia Foundation says one in 12 people in Australia are at risk of being diagnosed with a blood cancer, but a lack of awareness about symptoms means many cancers go undiagnosed for longer periods.The Foundation says blood cancers are likely to overtake other cancers by 2035.

This week's show is called "Insurance: Are You Covered?" with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series Right Thinking: Life, Money, Relationships. This week taking a look at how important it is to have a good insurance program in your life. Think you can't afford it? Think twice as you understand the consequences when something goes really wrong.https://www.talknetworkradio.com/hosts/right-thinking

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "Debt: Your Obligations to Others" with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series Right Thinking: Life, Money, Relationships. This week, we are discussing how we all have obligations to others, but do we manage them in a way that adds value to our lives, or are we controlled by them?https://www.talknetworkradio.com/hosts/right-thinking

Cancer can be lonely and isolating. Meet a patient who has started a special support group to help fellow cancer patients.

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "Credit: Doing What You Say You Are Going To Do" with guest Johnnie Lloyd.  Tune in and hear Steve and Johnnie continue their series Right Thinking: Life, Money, Relationships. One of the most important things that a person must do to have a healthy financial life is have good credit. This show will help you do that.https://www.talknetworkradio.com/hosts/right-thinking

Former NFL star Rick Upchurch seemed to be in good health, but in 2010, he began to experience night sweats, fatigue and aches and pains.  He saw his doctor, who ordered blood work.  The test results revealed his white blood cell count was very high, and his general practitioner gave him the address of another doctor to see.   Rick and his wife were shocked to learn the doctor they had been told to see was an oncologist.  That doctor called for a bone marrow biopsy, which confirmed Rick had chronic myelogenous leukemia, a rare form of blood cancer that is tied to a genetic mutation called Philadelphia chromosome.   The onocologist prescribed a chemotherapy regimen for Rick, but to some degree he was relieved to learn that it would be a regimen of oral chemotherapy.  The medication was known as tasigna, which also goes by the name of nilotinib.  Rick had to take these pills three times a day, which he still has to do, and will have to do for the rest of his life.   Rick Upchurch's chemotherapy regimen led to survivorship, but again, he has to take the tasigna three times a day, something he will need to do for the rest of his life.  He has his good days and bad days.   On the bad days, he still experiences the fatigue, night sweats, achy muscles and joints; and he sometimes has diarrhea, as his body has a tough time processing the tasigna.  However, he is grateful to be alive and grateful for the good days, in which he can lift weights, get on the elliptical and go for walks.   Rick and his wife, Donna, also engage in a number of activities that support children with cancer.

Jeffrey Magee, MD, PhD, Washington University School of Medicine, St. Louis, MO Recorded on April 3, 2025 Jeffrey Magee, MD, PhD Elizabeth H. and James S. McDonnell III Professor of Pediatrics Director, McDonnell Pediatric Cancer Center Division of Pediatric Hematology and Oncology Washington University School of Medicine St. Louis, MO In this episode, we sit down with Dr. Jeffrey Magee from the McDonald Pediatric Cancer Center at the Washington University School of Medicine in St. Louis to discuss the evolving landscape of pediatric blood cancers. Reflecting on his work, Dr. Magee shares, “One of the things I really love about the job is that it operates right at the interface between the science and the professional practice of medicine.” He examines groundbreaking advances bringing new hope to children and their families, from novel therapies and CAR T-cell therapy to the crucial role of clinical trials. Dr. Magee also speaks candidly about the challenges of delivering difficult news and shares compassionate strategies for supporting families through their toughest moments. Join us for this insightful and informative conversation on the future of pediatric blood cancer care today!

A simple cheek swab could mean the difference between life and death for a patient with blood cancer.

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "Reality Check," with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series Right Thinking: Life, Money, Relationships, this week with the sixth episode. Will the way that you handle your money work for you in the future, or will it cave in on you? Steve and Johnnie will teach you how to find out.https://www.talknetworkradio.com/hosts/right-thinking

As part of the Leukemia & Lymphoma Society Visionaries of the Year fundraising campaign, I will be highlighting the humans in front of blood cancer. This week, we highlight Kristen!  To donate to our fundraising campaign, go to: https://pages.lls.org/voy/sun/sun25/ccometa To watch the full interview: https://youtu.be/IKdqGiPJjV4

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "The Substitution Principle," with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series on Right Thinking. This week, they will focus on the Substitution Principle.  Once you realize what you are doing with your money, you can choose alternative ways to use it. The choice is yours!https://www.talknetworkradio.com/hosts/right-thinking

Imagine your doctor could precisely predict your personal risk of disease, diagnose the cause of illness with pinpoint accuracy when it did occur, and develop an effective treatment plan with low side effects the first time, rather than through trial and error. That's the promise of personalized medicine. And it would be a revolution in healthcare. At the heart of this vision is the notion that our genetic differences have a big impact on how each of us responds to disease and treatment. To realize a future of personalized medicine then, we need to understand and investigate just how genetic variations, including mutations, contribute to illness and respond to doctors' attempts to address it. But how can scientists do that efficiently with a human genome that spans about three billion base pairs of DNA across tens of thousands of genes? That's where the work of PhD student Dawn Chen comes in. A student in Harvard's Department of Stem Cell and Regenerative Biology and the Systems, Synthetic, and Quantitative Biology Program, Chen was named a recipient of the 2025 Harold M. Weintraub Graduate Student Award for Outstanding Achievement and Exceptional Research in the Biological Sciences, presented by Seattle's Fred Hutch Cancer Center. With her colleagues in the lab of Harvard professor Fei Chen, Dawn Chen is developing an innovative gene-editing tool known as helicase-assisted continuous editing, or HACE. A breakthrough in genetic engineering, supported in part by funds from the National Institutes of Health, HACE makes edits to specific genes, allowing researchers to investigate how genetic variations contribute to disease. The technique could lead to the identification of specific mutations that influence the effectiveness of drugs and therapies for illnesses like cancer. 

As part of the Leukemia & Lymphoma Society Visionaries of the Year fundraising campaign, I will be highlighting the humans in front of blood cancer. This week, I am sharing my personal journey with my Dad! To donate to our fundraising campaign, go to: https://pages.lls.org/voy/sun/sun25/ccometa  

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "No More Robbing Peter to Pay Paul" with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series on Right Thinking: Life, Money, Relationships. This week they discuss the Importance of Cash Flow Budgeting and Savings.https://www.talknetworkradio.com/hosts/right-thinking

As part of the Leukemia & Lymphoma Society Visionaries of the Year fundraising campaign, I will be highlighting the humans in front of blood cancer. This week, we highlight Denise and her Aunt Denise!  To donate to our fundraising campaign, go to: https://pages.lls.org/voy/sun/sun25/ccometa If you know Denise, please donate here: https://pages.lls.org/voy/sun/sun25/ddevonish To see the full video interview: https://youtu.be/nEAqS2cXorg  

Right Thinking with Steve Coplon.This week's show is called "A Picture is Worth a Thousand Words" with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series on Right Thinking, this week discussing the fifth Topic Paper: Keeping Track of Spending and the importance of seeing it on paper.https://www.talknetworkradio.com/hosts/right-thinking

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Gregory Monohan, MD,  Professor, Division of Hematology and Blood Marrow Transplant, UK Markey Cancer Center Cancer Conversations Episode 62 Dive into the latest episode of Cancer Conversation on Talking FACS, where host Mindy McCulley from the University of Kentucky Family and Consumer Sciences Extension is joined by Dr. Gregory Monohan, a professor of medicine in the Division of Hematology and Blood Marrow Transplant. In this insightful discussion, they explore groundbreaking advancements in the diagnosis and treatment of blood cancers, including leukemias, lymphomas, and multiple myeloma. Dr. Monohan sheds light on the complexities of blood cancer classifications and the significant progress made in developing targeted therapies tailored to various subtypes. The episode highlights the pivotal role of immunotherapy, introducing CAR-T therapy, bispecific antibodies, and TIL therapy as cutting-edge approaches revolutionizing patient outcomes. Listeners will gain a deeper understanding of the risk factors, symptoms, and innovative treatment methods that leverage the body's immune system to combat blood cancers. Whether you are a patient, a caregiver or simply curious about the latest cancer treatments, this episode offers valuable insights into the evolving landscape of blood cancer care. Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On Twitter @UKMarkey

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "When You Set Goals, They are Easier to Achieve," with guest Johnnie Lloyd. Tune in and hear Steve and Johnnie continue their series on Right Thinking, this week focusing on setting and achieving goals. Steve introduces his “Topic Papers,” a tool to help you budget your way to success.https://www.talknetworkradio.com/hosts/right-thinking

As part of the Leukemia & Lymphoma Society Visionaries of the Year fundraising campaign, I will be highlighting the humans in front of blood cancer. This week, we highlight Jill White and her journey with her Dad! To donate to our fundraising campaign, go to: https://pages.lls.org/voy/sun/sun25/ccometa To watch the video interview, go to: https://youtu.be/iaGF2qNHCBY  

Right Thinking with Steve Coplon | Guest: Johnnie LloydThis week's show is called "Right Thinking: Life Money Relationships with guest Johnnie Lloyd." Tune in and be with Steve and Johnnie as they begin a new series on financial literacy and the why they both have committed their lives to teaching it.https://www.talknetworkradio.com/hosts/right-thinking

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

Right Thinking with Steve Coplon.This week's show is called "It's Not Rocket Science." Tune in and hear Steve review the powerful message that Lefford Fate delivered in Episode 419 – Encore Edition # 313 on personal finances. We should all learn to thrive and not just exist.https://www.talknetworkradio.com/hosts/right-thinking

As part of the Leukemia & Lymphoma Society Visionaries of the Year fundraising campaign, I will be highlighting the humans in front of blood cancer. This week, we highlight Kiley King! To donate to our fundraising campaign, go to: https://pages.lls.org/voy/sun/sun25/ccometa To watch the video interview, go to: https://youtu.be/HWTJj2PsakE  

Right Thinking with Steve Coplon | Guest Host: Lefford FateThis week's show is called "Financial Wisdom with guest Lefford Fate." Tune in and hear Lefford share with Steve how a 17-year-old with no sense of purpose or direction became a man who eventually got it right. This show will focus on how having financial stability will help you have a better life. You will benefit from Lefford's straightforward, honest conversation.https://www.talknetworkradio.com/hosts/right-thinking

As part of the Leukemia & Lymphoma Society Visionaries of the Year fundraising campaign, I will be highlighting the humans in front of blood cancer. This week, we highlight our Honored Hero - Lana! To donate to our fundraising campaign, go to: https://pages.lls.org/voy/sun/sun25/ccometa To watch the video interview, go to: https://youtu.be/sZT62AsdZ58  

Right Thinking with Steve Coplon.This week's show is called "Back to the Basics." Tune in and hear Steve share his thoughts on the progress that Right Thinking Foundation is making as it forges ahead with its mission to help people have a better life.https://www.talknetworkradio.com/hosts/right-thinking

BUFFALO, NY - February 10, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation." In this case report, Aleksandra Mroczkowska-Bękarciak and Tomasz Wróbel from Wroclaw Medical University describe a rare and serious complication after a stem cell transplant. The case involves a patient who, nine years after receiving a stem cell transplant for acute myeloid leukemia (AML), developed a new, aggressive blood cancer originating from donor cells. Despite receiving treatment, the disease progressed to myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), ultimately leading to the patient's death. Stem cell transplants are a life-saving treatment for many blood cancers, including AML. While relapse of the original cancer is the most common concern, this case highlights another rare but serious complication: the development of donor cell-derived hematologic neoplasms (DCHN). The report details the case of a 23-year-old woman who remained in remission for nearly 10 years following a successful hematopoietic stem cell transplant from an unrelated donor. However, she later developed a new form of leukemia, driven by genetic mutations in the ASXL1, SETBP1, and EZH2 genes—biomarkers linked to highly aggressive blood cancers. Over the next two years, the disease progressed despite intensive treatment, ultimately proving fatal. This case highlights the need for continued monitoring of transplant recipients, even years after the procedure. Although DCHN is extremely rare, its occurrence raises critical questions about the process by which donor cells transform into leukemia. Some stem cell donors may unknowingly carry genetic mutations that are harmless in their own bodies but could trigger cancer in recipients. Additionally, factors such as immunosuppressive therapy, bone marrow stress, and transplantation procedures may contribute to these rare but deadly outcomes. “Early diagnosis and intervention are crucial to improving patient prognosis.” Ongoing research is focused on improving donor screening methods to help predict and prevent these complications. In the future, routine genetic testing for stem cell donors could become a standard part of the transplant process, helping clinicians identify potential risks before transplantation. More studies are needed to fully understand why donor-derived cancers develop and how they can be prevented. With continued progress in precision medicine and genetic diagnostics, researchers aim to make stem cell transplants safer and more effective for all patients. DOI - https://doi.org/10.18632/oncotarget.28686 Correspondence to - Aleksandra Mroczkowska-Bękarciak - omroczkowska@interia.pl Video short - https://www.youtube.com/watch?v=G2zd0UqWzeE About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Right Thinking with Steve Coplon.This week's show is called "Oh - What A Blessing!" Tune in and hear Steve reflect on what a blessing his life is as he shares two letters from inmates that he had the privilege to meet along the way. It is really amazing how when you are working for the Lord, your life is so very beautiful.In this episode titled "Oh - What a Blessing!" I reflect on the profound experiences I've encountered through my prison ministry work, particularly the hundreds of letters from inmates I've received. As I've navigated personal challenges, including health issues, I embrace a journey of decluttering that prompts deep introspection about the significance of the items we collect and the impact of my service on others' lives.Conversations with Pastor Richard Wilcox illuminate the concept of agape love, driving home the importance of selfless service without expectation. I share transformative stories from inmates like Joseph and Steva, showcasing how connections built through encouragement and knowledge can inspire change. Ultimately, I encourage listeners to focus on their legacy and the spiritual rewards of serving their communities, emphasizing the blessings that come from a life dedicated to uplifting others.https://www.talknetworkradio.com/hosts/right-thinking

Tommy Stackhouse was diagnosed with Acute Myeloid Leukemia just two weeks before his 16th birthday in May of 2019. Tommy graduated from High School and during his senior year he was voted Homecoming King. After two Stem Cell Transplants and while Tommy was studying at a Community College, Tommy's health became a serious problem and he passed away from this most difficult form of Blood Cancer on May 26th of 2022. 

Blood isn't just thicker than water—it's a lifeline, and sometimes it needs saving. In this special three-part episode, we explore leukemia and lymphoma from every angle. First, survivor Leanne Kean opens up about the grit, hope, and humour it took to reclaim her life after cancer. Next, Dr. Mani Larijani reveals the groundbreaking research reshaping blood cancer treatment and offering new hope to patients. Finally, Daniel Blacquiere from the Leukemia & Lymphoma Society of Canada highlights how donations power these life-saving advancements. It's an emotional, eye-opening journey into the science, stories, and spirit of the fight against blood cancer.For more information on how you can support those battling Leukemia & Lymphoma visit: https://www.bloodcancers.ca/Catch the full video version of this episode on YouTube.Follow Sickboy on TikTok, Instagram and Discord!